GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

被引：0
|
作者：
Coates, L. C. [1 ]
Ritchlin, C. T. [2 ]
Gossec, L. [3 ]
Helliwell, P. [4 ]
Rahman, P. [5 ]
Hsia, E. C. [6 ,7 ]
Kollmeier, A. [8 ]
Xu, X. L. [8 ]
Karyekar, C. [9 ]
Shawi, M. [9 ]
Noel, W. [10 ]
Jiang, Y. [11 ]
Sheng, S. [11 ]
Wang, Y. [11 ]
Mease, P. J. [12 ,13 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[2] Univ Rochester, Med Ctr, Dept Med AllergyImmunol & Rheumatol, Rochester, NY 14642 USA
[3] Sorbonne Univ, Rheumatol, Paris, France
[4] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[5] Mem Univ Newfoundland, Craig L Dobbin Genet Res Ctr, St John, NF, Canada
[6] Janssen Res & Dev LLC, Immunol, Spring House, PA USA
[7] Univ Penn, Rheumatol, Philadelphia, PA 19104 USA
[8] Janssen Res & Dev LLC, Immunol, La Jolla, CA USA
[9] Janssen Res & Dev LLC, Immunol, Horsham, PA USA
[10] Janssen Res & Dev LLC, Immunol, Brussels, Belgium
[11] Janssen Res & Dev LLC, Biostat, Spring House, PA USA
[12] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[13] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.167
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1024
引用
收藏
页码：781 / 782
页数：2
相关论文
共 50 条
  • [31] Changes in Serum Cytokines and Collagen Proteins Correlate with Durability of Guselkumab Efficacy and Continued Disease Improvement Through 2 Years in Patients with Active Psoriatic Arthritis
    Siebert, Stefan
    Schett, Georg
    Raychaudhuri, Siba
    Guma, Monica
    Chen, Warner
    Gao, Sheng
    Chakravarty, Soumya
    Shawi, May
    Rahman, Proton
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2787 - 2789
  • [32] Efficacy of guselkumab (GUS) on axial-related endpoints in patients with active psoriatic arthritis (PsA) with imaging-confirmed sacroiliitis: Results through week 52 from DISCOVER-1 and DISCOVER-2
    Gottlieb, Alice B.
    Merola, Joseph F.
    Armstrong, April W.
    Savage, Laura
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Zhou, Bei
    Yang, Ya-Wen
    Sweet, Kristen
    Boehncke, Wolf-Henning
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB39 - AB39
  • [33] Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two-Year Results from a Phase 3 Trial
    Helliwell, Philip
    Lespessailles, Eric
    Shuler, Catherine
    Mallbris, Lotus
    Erickson, Janelle
    Fleischmann, Roy
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 998 - 999
  • [34] Domain-Specific Evaluation of Inflammatory Burden in Psoriatic Arthritis Using Total-Body [18F]FDG PET/CT
    Abdelhafez, Yasser
    Raychaudhuri, Siba
    Mazza, Dario
    Raychaudhuri, Smriti
    Cherry, Simon
    Nardo, Lorenzo
    Badawi, Ramsey
    Chaudhar, Abhijit
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [35] Secukinumab provides sustained inhibition of radiographic progression in active psoriatic arthritis patients: 52-week results from future 5 study
    Mease, P.
    Heijde, D. V. D.
    Landewe, R.
    Mpofu, S.
    Rahman, P.
    Tahir, H.
    Singhal, A.
    Boettcher, E.
    Navarra, S.
    Zhu, X.
    Readie, A.
    Pricop, L.
    Abrams, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 84 - 84
  • [36] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
    Hall, S.
    Mease, P.
    Kavanaugh, A.
    Reimold, A.
    Tahir, H.
    Rech, J.
    Geusens, P.
    Pascale, P.
    Delicha, E.
    Pricop, L.
    Mpofu, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 37 - 38
  • [37] Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials
    Pushpike Thilakarathne
    Agata Schubert
    Steve Peterson
    Wim Noel
    Barkha P. Patel
    Fareen Hassan
    Rheumatology and Therapy, 2024, 11 : 457 - 474
  • [38] Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials
    Thilakarathne, Pushpike
    Schubert, Agata
    Peterson, Steve
    Noel, Wim
    Patel, Barkha P.
    Hassan, Fareen
    RHEUMATOLOGY AND THERAPY, 2024, 11 (02) : 457 - 474
  • [39] Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
    Nash, Peter
    Ohson, Kamal
    Walsh, Jessica
    Delev, Nikolay
    Nguyen, Dianne
    Teng, Lichen
    Gomez-Reino, Juan J.
    Aelion, Jacob A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (05) : 690 - 698
  • [40] SUBCUTANEOUS SECUKINUMAB PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
    Mease, Philip
    van der Heijde, Desiree
    Landewe, Robert
    Mpofu, Shephard
    Rahman, Proton
    Tahir, Hasan
    Singhal, Atul
    Boettcher, Elke
    Navarra, Sandra
    Zhu, Xuan
    Readie, Aimee
    Abrams, Ken
    Pricop, Luminita
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S10 - S10
12345